重组人干扰素α1b注射液雾化吸入对小儿毛细支气管炎的疗效及预后  

Efficacy and Prognosis of Aerosol Inhalation of Recombinant Human Interferonα1b Injection on Bronchiolitis in Children

作　　者：周雯雯[1] ZHOU Wenwen(Zhuhai Maternal and Child Health Hospital,Zhuhai 519000,China)

机构地区：[1]珠海市妇幼保健院,广东珠海519000

出　　处：《中外医学研究》2021年第28期172-174,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨重组人干扰素α1b注射液雾化吸入对小儿毛细支气管炎的疗效及预后。方法:选取2019年1月-2020年1月笔者所在医院儿科收治的92例小儿毛细支气管炎患儿作为研究对象,采用随机数字表法将其分为观察组和对照组,各46例。对照组接受常规治疗,观察组在对照组基础上给予配合重组人干扰素α1b注射液雾化吸入治疗。比较两组临床疗效、治疗前后肺功能指标及症状消失时间。结果:观察组治疗总有效率为97.83%,高于对照组的78.26%,差异有统计学意义(P<0.05)。治疗前,两组TI/TE、Rrs及VT/kg水平比较差异均无统计学意义(P>0.05);治疗后,观察组TI/TE、Rrs及VT/kg水平均优于对照组,差异有统计学意义(P<0.05)。观察组憋喘、咳嗽、哮鸣音消失时间均明显早于对照组,差异有统计学意义(P<0.05)。结论:对小儿毛细支气管炎患儿予以重组人干扰素α1b注射液雾化吸入治疗,可以有效改善肺功能,缩短症状消失时间,提高治疗效果,促进病情尽早康复,应用价值显著,值得推广。Objective:To investigate the efficacy and prognosis of aerosol inhalation of Recombinant Human Interferonα1b Injection on bronchiolitis in children.Method:A total of 92 children with bronchiolitis admitted in the department of pediatrics of our hospital from January 2019 to January 2020 were selected as the research objects.They were divided into the observation group and the control group by random number table method,with 46 cases in each group.The control group received routine treatment,and the observation group was given aerosol inhalation of Recombinant Human Interferon α1b Injection on the basis of the control group.The clinical efficacy,lung function indexes before and after treatment and the symptom disappearance time were compared between the two groups.Result:The total effective rate of the observation group was 97.83%,which was higher than 78.26% of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in TI/TE,Rrs and VT/kg between the two groups(P>0.05).After treatment,the levels of TI/TE,Rrs and VT/kg in the observation group were better than those in the control group,and the differences were statistically significant(P<0.05).The disappearance time of asthma,cough and wheezing in the observation group were significantly earlier than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Aerosol inhalation of Recombinant Human Interferon α1b Injection on bronchiolitis in children can effectively improve the lung function,shorten the symptom disappearance time,improve the therapeutic effect,and promote the early recovery of the disease.The application value is significant and worthy of promotion.

关 键 词：小儿毛细支气管炎 重组人干扰素Α1B 雾化吸入 肺功能 

分 类 号：R725.6[医药卫生—儿科]